MA40583A - Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation - Google Patents

Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation

Info

Publication number
MA40583A
MA40583A MA040583A MA40583A MA40583A MA 40583 A MA40583 A MA 40583A MA 040583 A MA040583 A MA 040583A MA 40583 A MA40583 A MA 40583A MA 40583 A MA40583 A MA 40583A
Authority
MA
Morocco
Prior art keywords
guanylate cyclase
soluble guanylate
cyclase activators
novel soluble
activators
Prior art date
Application number
MA040583A
Other languages
English (en)
Inventor
Anne Marie Jeanne Bouillot
Nerina Dodic
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA40583A publication Critical patent/MA40583A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne des activateurs de la guanylate cyclase soluble, de formule générique (i), et leur utilisation dans des compositions pharmaceutiques, principalement des compositions ophtalmiques administrées par voie topique. Les compositions pharmaceutiques sont utilisables pour réduire la pression intra-oculaire chez les animaux d'espèces de mammifères.
MA040583A 2014-09-19 2015-09-18 Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation MA40583A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462052537P 2014-09-19 2014-09-19

Publications (1)

Publication Number Publication Date
MA40583A true MA40583A (fr) 2016-03-24

Family

ID=54238488

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040583A MA40583A (fr) 2014-09-19 2015-09-18 Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation

Country Status (21)

Country Link
US (2) US9938260B2 (fr)
EP (1) EP3194384A1 (fr)
JP (3) JP6678656B2 (fr)
KR (1) KR20170054508A (fr)
CN (1) CN106687456B (fr)
AU (1) AU2015319724B2 (fr)
BR (1) BR112017005660A2 (fr)
CA (1) CA2961745A1 (fr)
CL (1) CL2017000640A1 (fr)
CO (1) CO2017002506A2 (fr)
CR (1) CR20170102A (fr)
DO (1) DOP2017000073A (fr)
EA (1) EA033697B1 (fr)
IL (1) IL251094A0 (fr)
MA (1) MA40583A (fr)
MX (1) MX2017003621A (fr)
PE (1) PE20170937A1 (fr)
PH (1) PH12017500481A1 (fr)
SG (1) SG11201701915TA (fr)
WO (1) WO2016042536A1 (fr)
ZA (1) ZA201701835B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3102568T3 (pl) 2014-02-06 2019-01-31 Heptares Therapeutics Limited Bicykliczne związki aza w postaci agonistów receptorów muskarynowych m1
CR20170100A (es) 2014-09-19 2017-04-24 Bayer Pharma Aktiengesellchaft Indazoles sustituidos con bencilo como inhibidores bub1
SG11201701915TA (en) * 2014-09-19 2017-04-27 Glaxosmithkline Ip Dev Ltd Novel soluble guanylate cyclase activators and their use
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
WO2019081456A1 (fr) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Utilisation d'activateurs et de stimulateurs de sgc comprenant une sous-unité bêta2
EP3498298A1 (fr) 2017-12-15 2019-06-19 Bayer AG Utilisation de stimulateurs sgc et d'activateurs sgc seuls ou en combinaison avec des inhibiteurs pde5 pour le traitement de troubles osseux, y compris l'ostéogénèse imparfaite (oi)
WO2019211081A1 (fr) 2018-04-30 2019-11-07 Bayer Aktiengesellschaft Utilisation d'activateurs de la gcs et de stimulateurs de la gcs pour le traitement de déficiences cognitives
CA3100096A1 (fr) 2018-05-15 2019-11-21 Bayer Aktiengesellschaft Benzamides a substitution 1,3-thiazol-2-yl pour le traitement de maladies associees a la sensibilisation de fibres nerveuses
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
CA3126778A1 (fr) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Procedes permettant de determiner si un sujet est apte a etre traite avec un agoniste de guanylyle cyclase soluble (sgc)
EP4536205A1 (fr) 2022-06-09 2025-04-16 Bayer Aktiengesellschaft Activateurs de guanylate cyclase soluble destinés à être utilisés dans le traitement de l'insuffisance cardiaque à fraction d'éjection préservée chez les femmes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602143A (en) 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
CN101553206B (zh) * 2006-11-09 2012-11-21 爱尔康研究有限公司 用于药物递送的水不溶性聚合物基质
PE20091258A1 (es) 2007-12-03 2009-09-12 Smithkline Beecham Corp Derivados de piridina como activadores de la guanilato ciclasa soluble
WO2010015653A1 (fr) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Dérivés de pyrimidine comme activateurs de guanylate cyclase soluble
EP2401265B1 (fr) * 2009-02-26 2016-09-14 Merck Sharp & Dohme Corp. Derives d'acide 1-pyri(mid)in-2-yl-pyrazole-4-carboxylique utiles dans la therapie ou la prophylaxie de maladies cardiovasculaires
DE102009012314A1 (de) * 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
JP5636296B2 (ja) 2011-01-20 2014-12-03 公益財団法人微生物化学研究会 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体
SG11201701915TA (en) * 2014-09-19 2017-04-27 Glaxosmithkline Ip Dev Ltd Novel soluble guanylate cyclase activators and their use

Also Published As

Publication number Publication date
US10472350B2 (en) 2019-11-12
EP3194384A1 (fr) 2017-07-26
CO2017002506A2 (es) 2017-07-28
SG11201701915TA (en) 2017-04-27
MX2017003621A (es) 2017-07-14
JP6908747B2 (ja) 2021-07-28
BR112017005660A2 (pt) 2017-12-19
CN106687456B (zh) 2019-12-03
AU2015319724B2 (en) 2018-05-10
JP6678656B2 (ja) 2020-04-08
PE20170937A1 (es) 2017-07-13
KR20170054508A (ko) 2017-05-17
US20180194756A1 (en) 2018-07-12
PH12017500481A1 (en) 2017-08-07
US20170305888A1 (en) 2017-10-26
US9938260B2 (en) 2018-04-10
CR20170102A (es) 2017-07-17
JP2020105189A (ja) 2020-07-09
EA201790655A1 (ru) 2017-08-31
WO2016042536A1 (fr) 2016-03-24
CN106687456A (zh) 2017-05-17
AU2015319724A1 (en) 2017-04-06
JP2017527602A (ja) 2017-09-21
EA033697B1 (ru) 2019-11-18
CL2017000640A1 (es) 2017-10-06
CA2961745A1 (fr) 2016-03-24
IL251094A0 (en) 2017-04-30
JP2021155450A (ja) 2021-10-07
DOP2017000073A (es) 2017-04-16
ZA201701835B (en) 2018-12-19

Similar Documents

Publication Publication Date Title
MA40583A (fr) Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MX2015010125A (es) Derivados de piridazinona-amidas.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
TW201613864A (en) Novel compounds
MY198018A (en) Aminothiazole derivatives useful as antiviral agents
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MY181641A (en) Amino pyran ring derivative and composition and use thereof
PH12015502118A1 (en) Pyridin-4-yl derivatives
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
MX376090B (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas.
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
TN2016000490A1 (en) Naphthyridinedione derivatives.
PH12018502376B1 (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
GEAP201814266A (en) Pyrazines modulators of gpr6